Summary of Harvard Bioscience Conference Call Company Overview - **Company**: Harvard Bioscience (NasdaqGM: HBIO) - **Date**: March 17, 2026 - **Speakers**: John Duke (CEO), Mark Frost (CFO) Key Points Company Strategy and Leadership - John Duke has over 10 years in the life science industry, previously CEO of a private equity-owned company before joining Harvard Bioscience in July 2025 [2] - The company has recently refinanced short-term debt, which was a significant focus [2] - Harvard Bioscience has a diverse product portfolio, with 54% of products being recurring, including consumables and software [3] Market Growth Areas - The organoid market is growing at a rate of 15%-20%, which is a key area of focus for the company [6] - The BTX product line in bioproduction is also highlighted as a growth area, with a cGMP product launch expected in the second half of the year [8] - The company aims to maintain leadership in its SoHo telemetry platform [6] Competitive Landscape - Competitors in the organoid space include Axion BioSystems, MaxWell Biosystems, and 3Brain, with Harvard's unique Mesh MEA system providing a competitive edge [9] - The organoid products have seen increased adoption in pharmaceutical companies, expanding beyond research institutes [10] Regulatory Environment - The FDA's promotion of cell-based research is seen as complementary to Harvard's business, with expectations that animal testing will remain relevant in the near term [11] - The company anticipates a gradual shift towards new methodologies over the next 10-20 years [12] Financial Performance and Guidance - In 2025, revenue distribution was 50% from academic institutions, 28% from pharma and biotech, and 22% from contract research organizations [15] - The company expects NIH funding to remain flat at 1% for the year, with new products projected to double their contribution to revenue from 5% to 10% [18] - Debt service costs are expected to decrease from $8 million to $5 million over the next two years, allowing for additional cash flow for investment [38] Product Development and Innovation - New products introduced include the Mesh MEA and Incub8 platform for organoid research, and new telemetry implants [21] - The company is consolidating manufacturing to improve efficiency and reduce costs, with expectations of significant gross margin improvements [53] Market Conditions and Future Outlook - The contract research marketplace is expected to remain flat to low single digits in growth for the year [31] - There are signs of recovery in the biotech market, particularly among large pharma and biotech companies [34] - The company is optimistic about growth potential, aiming for EBITDA margins to reach low 20% levels in the future [60] Distribution and Market Reach - Distribution is split 39% through distributors and 61% direct sales, with a focus on expanding the sales force [43] - The company is seeing recovery in the Chinese market after previous tariff impacts, with expectations for improved orders in Q2 [44] Non-Core Business and Margin Improvement - Harvard Bioscience has removed $8 million-$10 million in non-core revenue over the past five years, resulting in improved gross margins [47] - Current gross margins are reported at 58%-60%, with expectations to increase through new product introductions and cost reductions [49] Conclusion - Harvard Bioscience is positioned for growth with a focus on innovative products, strategic market expansion, and improved financial health through debt management and operational efficiencies [69]

Core Insights - Hologic and Thermo Fisher Scientific are key players in the diagnostics market, each with distinct strengths and market focuses [1][2] Hologic Overview - Hologic specializes in molecular diagnostic assays for infectious diseases, particularly in women's health, with a market cap of $14.75 billion [1] - The company has seen strong growth in its Molecular Diagnostics segment, particularly with the BV, CV/TV assay, which has become its second-largest test globally since its launch in 2019 [3] - Hologic's Breast Health business is recovering, with expectations to return to growth by Q4 of fiscal 2025, aided by new leadership and innovations [4] - The company has a strong GYN Surgical portfolio and has expanded its fibroid treatment offerings through the acquisition of Gynesonics [5] - Hologic maintains a solid financial position with $1.88 billion in cash and short-term investments and a net leverage ratio of 0.6 [6] - The company has raised its full-year revenue guidance to $1.03-$1.04 billion and adjusted EPS to $1.09-$1.12, despite facing cost pressures from tariffs [7] Thermo Fisher Overview - Thermo Fisher, valued at $181.10 billion, offers a wide range of diagnostic products and services across various sectors, including healthcare and food safety [2] - The company is experiencing growth in its bioproduction and pharma services, supported by significant innovations and product launches [8] - Thermo Fisher's capital deployment strategy includes strategic acquisitions and shareholder returns, with recent acquisitions aimed at enhancing its bioproduction capabilities [11] - The company has projected revenues between $43.6 and $44.2 billion and adjusted EPS of $22.22-$22.84 for the full year, both raised from prior estimates [13] Performance Comparison - Over the last six months, Hologic's stock has increased by 4.2%, while Thermo Fisher's stock has decreased by 7.7% [9][16] - Hologic's shares are trading at a forward five-year P/E of 14.41X, compared to Thermo Fisher's P/E of 20.12X, indicating a more favorable valuation for Hologic [17] - Analysts project a year-over-year EPS growth of 3.7% for Hologic, while Thermo Fisher's EPS is expected to improve by 3% [19][21] Investment Outlook - Both companies exhibit strong fundamentals and financial stability, with Hologic showing resilience in its growth areas and Thermo Fisher focusing on innovation and market expansion [22]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $21.8 million, down from $24.5 million in Q1 2024, aligning with the higher end of guidance [7][10] - Gross margin decreased to 56% from 60.3% in the previous year [8][14] - Operating loss was $49.7 million compared to a loss of $2.3 million in Q1 2024, primarily due to a goodwill impairment charge of $48 million [8][10] - Adjusted EBITDA was $800,000, down from $1.6 million in Q1 2024 [15] - Cash flow from operations improved to $3 million from $1.4 million in the prior year [16] Business Line Data and Key Metrics Changes - Revenue in The Americas declined 9.4% year-over-year and 5.4% sequentially [11] - European revenue decreased 29% sequentially and 9% year-over-year [12] - APAC revenue increased 6.6% sequentially but was down 17% compared to the prior year [13] Market Data and Key Metrics Changes - The Americas faced a slowdown attributed to budget clarity issues for academic and NIH funding [11] - European sales were impacted by a lack of seasonal bump and lower CRO sales [12] - APAC market showed slight sequential growth but anticipated challenges due to tariff announcements [13] Company Strategy and Development Direction - Focus on expanding adoption of new products while reducing costs, with an expected reduction in operating expenses by an additional $1 million per quarter starting Q2 2025 [25] - New product introductions include the SOHO telemetry devices and VivaMARS system, targeting both academic and industrial customers [19][20] - Emphasis on bioproduction applications and exploring partnerships for CAR T therapy production [21][31] Management's Comments on Operating Environment and Future Outlook - Management expressed concerns over NIH funding and the impact of tariffs on revenue, particularly in China [25][53] - Positive outlook on the adoption of organoid systems due to government policy changes encouraging alternative testing methods [24][34] - Anticipated Q2 revenue guidance is between $18 million to $20 million, with gross margin expected to be in the 55% to 57% range [25] Other Important Information - Goodwill impairment charge of $48 million was recorded due to a decrease in market capitalization [10][29] - Net debt decreased to $30.8 million, reflecting improved cash flow management [16] Q&A Session Summary Question: Can you elaborate on the impairment charge? - Management explained that the impairment was due to a drop in market cap, necessitating a reassessment of goodwill, leading to a non-cash charge of $48 million [29] Question: What about the bioproduction business and CAR T therapy? - Management confirmed that the BTX system is being adopted by a domestic biotech for CAR T therapy production, indicating strong traction in the market [31] Question: How is the MEA product line performing amid NIH funding uncertainties? - Management noted strong interest in the MEA product line, particularly from academic researchers, despite a slowdown in purchasing processes due to NIH staffing changes [34][45] Question: What are the refinancing plans? - Management indicated that refinancing will be more expensive than commercial rates, with terms likely spanning four to five years [46][48]